281 related articles for article (PubMed ID: 22575381)
1. Angiogenesis: a promising therapeutic target for ovarian cancer.
Bamias A; Pignata S; Pujade-Lauraine E
Crit Rev Oncol Hematol; 2012 Dec; 84(3):314-26. PubMed ID: 22575381
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab in the treatment of ovarian cancer.
Han ES; Monk BJ
Expert Rev Anticancer Ther; 2007 Oct; 7(10):1339-45. PubMed ID: 17944559
[TBL] [Abstract][Full Text] [Related]
3. Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386).
Marchetti C; Gasparri ML; Ruscito I; Palaia I; Perniola G; Carrone A; Farooqi AA; Pecorini F; Muzii L; Panici PB
Crit Rev Oncol Hematol; 2015 Jun; 94(3):302-10. PubMed ID: 25783620
[TBL] [Abstract][Full Text] [Related]
4. Angiogenesis as a target for the treatment of ovarian cancer.
Shaw D; Clamp A; Jayson GC
Curr Opin Oncol; 2013 Sep; 25(5):558-65. PubMed ID: 23942301
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis as a strategic target for ovarian cancer therapy.
Spannuth WA; Sood AK; Coleman RL
Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
[TBL] [Abstract][Full Text] [Related]
6. Targeting angiogenesis in ovarian cancer.
Schmitt J; Matei D
Cancer Treat Rev; 2012 Jun; 38(4):272-83. PubMed ID: 21764518
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
8. Overview of anti-angiogenic agents in development for ovarian cancer.
Burger RA
Gynecol Oncol; 2011 Apr; 121(1):230-8. PubMed ID: 21215996
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
Aravantinos G; Pectasides D
J Ovarian Res; 2014; 7():57. PubMed ID: 24864163
[TBL] [Abstract][Full Text] [Related]
10. [Gynecologic cancer].
Sugiyama T; Takeuchi S; Fukagawa T
Gan To Kagaku Ryoho; 2014 Feb; 41(2):157-61. PubMed ID: 24743194
[TBL] [Abstract][Full Text] [Related]
11. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
Gubbi A; Kendrick JE; Finkler NJ
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma.
Gadducci A; Viacava P; Cosio S; Fanelli G; Fanucchi A; Cecchetti D; Cristofani R; Genazzani AR
Anticancer Res; 2003; 23(1B):549-56. PubMed ID: 12680144
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
Rosanò L; Spinella F; Salani D; Di Castro V; Venuti A; Nicotra MR; Natali PG; Bagnato A
Cancer Res; 2003 May; 63(10):2447-53. PubMed ID: 12750265
[TBL] [Abstract][Full Text] [Related]
15. Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.
Tomao F; Papa A; Rossi L; Caruso D; Zoratto F; Benedetti Panici P; Tomao S
Expert Opin Investig Drugs; 2014 Jan; 23(1):37-53. PubMed ID: 24111925
[TBL] [Abstract][Full Text] [Related]
16. [New drugs and targeted therapeutic agents in ovarian cancer].
de La Motte Rouge T; Petrella MC; Michels J; Even C; Balleyguier C; Duclos J; Mazeron R; Morice P; Pautier P; Lhommé C
Bull Cancer; 2009 Dec; 96(12):1215-24. PubMed ID: 19919916
[TBL] [Abstract][Full Text] [Related]
17. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
Eskander RN; Tewari KS
Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
[TBL] [Abstract][Full Text] [Related]
18. Is it time for some new approaches for treating advanced ovarian cancer?
McGuire WP
J Natl Cancer Inst; 2006 Aug; 98(15):1024-6. PubMed ID: 16882933
[No Abstract] [Full Text] [Related]
19. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
20. The future of targeted therapies in ovarian cancer.
Banerjee S; Gore M
Oncologist; 2009 Jul; 14(7):706-16. PubMed ID: 19592450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
